biostudies-literatureEllis JDNIDA NIH HHSNational Institute on Drug Abuse223-232https://www.ebi.ac.uk/biostudies/studies/S-EPMC8766934biostudies-literatureUnknown299<h4>Background</h4>Understanding the course of anxiety and depressive symptoms in early opioid use disorder (OUD) treatment may inform efforts to promote positive early treatment response and reduce treatment attrition.<h4>Methods</h4>Persons in treatment for nonmedical opioid use were identified from 86 addiction treatment facilities. Growth mixture modeling was used to identify trajectories of anxiety and depression symptoms during the first month of treatment among individuals who screened positive for depression (N = 3016) and/or anxiety (N = 2779) at intake.<h4>Results</h4>A three-class solution best fit the data for anxiety symptoms and included the following trajectories: (1) persistent moderate-to-severe anxiety symptoms, (2) remitting severe anxiety symptoms, and (3) persistent miJournal of affective disordersLatent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.PMC8766934T32 DA007209UG3DA048734UG3 DA048734Ellis JDRabinowitz JAWells JHobelmann GJStein MDIi DGAHuhn ASLiu FFinan PHfalseLatent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.<h4>Background</h4>Understanding the course of anxiety and depressive symptoms in early opioid use disorder (OUD) treatment may inform efforts to promote positive early treatment response and reduce treatment attrition.<h4>Methods</h4>Persons in treatment for nonmedical opioid use were identified from 86 addiction treatment facilities. Growth mixture modeling was used to identify trajectories of anxiety and depression symptoms during the first month of treatment among individuals who screened positive for depression (N = 3016) and/or anxiety (N = 2779) at intake.<h4>Results</h4>A three-class solution best fit the data for anxiety symptoms and included the following trajectories: (1) persistent moderate-to-severe anxiety symptoms, (2) remitting severe anxiety symptoms, and (3) persistent mi2022-01-01T00:00:00Z2022 Feb2026-06-04T04:05:42.184Z2025-04-19T13:27:48.147ZS-EPMC87669343487163810.1016/j.jad.2021.12.004